Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada

Emmaus Life Sciences, Inc.

Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.
Supply price is Emmaus' production cost plus a specified double-digit percentage margin.
Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.
Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).
Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).

Action: entry
Agreement: supply
Counterparty: NeoImmuneTech, Inc. (NIT)
Effective: 2026-03-02

Exact text from the filing

n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-023644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.